[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623402":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":45,"slug":11,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"The Skin Center Dermatology Group","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients receive nemolizumab injections every 4 weeks, weight based dosing","EXPERIMENTAL",null,[13],"Drug: Nemolizumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Nemolizumab","subcutaneous injection",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Peter Friedman, MD PhD","CONTACT","8453520500","drfriedman@skincenterderm.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","New City","New York","10956","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-73.98931,41.1476,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":24,"phoneExt":11,"email":25},"Peter C Friedman, MD PhD",{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623402",false,"NCT07396168","Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.","Inclusion Criteria:\n\n* Age ≥18 years.\n* Clinical and\u002For histopathologic diagnosis of LPP.\n* Presence of scalp pruritus.\n* Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.\n* Ability and willingness to provide written informed consent and comply with study procedures.\n* Willingness to undergo optional scalp biopsy for research purposes.\n\nExclusion Criteria:\n\n* Other forms of alopecia that may interfere with study assessments.\n* Any systemic disease associated with hair loss.\n* Inflammatory or infectious scalp disease that may interfere with the study.\n* Any other conditions associated with pruritus.\n* Prior use of nemolizumab.\n* Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).\n* Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks).\n* Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or\n* biologics.\n* Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks).\n* Any other current treatments for hair loss (e.g., oral\u002Ftopical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed.\n* Allergy or hypersensitivity to nemolizumab or any excipients.\n* Pregnancy or unwillingness to use highly effective contraception.\n* Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.","ALL","18 Years",{"count":53,"type":54},10,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.",[60],"Lichen Plano-Pilaris","2026-02-07",{"date":63,"type":64},"2026-02-10","ACTUAL",{"date":66,"type":64},"2026-02-01",{"date":68,"type":54},"2027-06",{"name":5,"class":6},1]